Drugs / AVOVA-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02033616 | Nov 2017 → Mar 2022 | fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma | Aivita Biomedical, Inc. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2020-04-27 | Aivita Biomedical, Inc. | Results AIVITA Biomedical Presents Updates from Ongoing Ovarian Cancer and Glioblastoma Clinical Studies at 2020 AACR Virtual Annual Meeting aivitabiomedical.com ↗
The presentation from Lisa Abaid, MD, principal investigator of the Phase 2 clinical trial of AVOVA-1 in advanced ovarian cancer, showed the trial is progressing as planned and the treatment has been well-tolerated. |
| 2019-02-12 | Aivita Biomedical, Inc. | Results AIVITA Identifies Mechanism to Enhance Patient Response Rate to Next Generation Cancer Stem Cell Immunotherapy aivitabiomedical.com ↗
Today, AIVITA announced new data indicating that non-responders to its immunotherapy had, on average, 150,000 times more pre-existing PD-1 proteins in their bloodstreams than responders. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-04-27 | Aivita Biomedical, Inc. | AIVITA Biomedical Presents Updates from Ongoing Ovarian Cancer and Glioblastoma Clinical Studies at 2020 AACR Virtual Annual Meeting aivitabiomedical.com ↗ |
| 2019-02-12 | Aivita Biomedical, Inc. | AIVITA Identifies Mechanism to Enhance Patient Response Rate to Next Generation Cancer Stem Cell Immunotherapy aivitabiomedical.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVOVA-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02033616 ↗ |
| Modality | Cell therapy | “Autologous dendritic cells loaded with tumor associated antigens (TAA) from autologous self-renewing tumor cells.” NCT02033616 ↗ |